This press release contains forward -looking statements that involve a number of risks and uncertainties, the outcome could affect materially and / or actual future results actual future results. Specifically, the risks and uncertainties that of pixantrone of pixantrone, risks with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular, including, without limitation, the results of complete safety and progression-free survival for pixantrone the is still mounted the potential failure of the potential failure of pixantrone to prove safe and effective for the treatment of relapsed aggressive NHL as the FDA, the determination of the FDA that the PIX301 study is insufficient to, an NDA, the company’s ability continue to support capital events or otherwise.cessary to its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company’s filings with the Securities and Exchange Commission including, without limitation that fund.
CTI intends to further evaluate additional details of the study and complete security and progression-free survival compared with treatment information tasks that currently deliver mounted for analysis.‘This novel medicines expands the treatment of arsenal of to make available, deliver immediate advantages, because it is effect rapidly, and no doubt features using for the people of African and Asian, which most affected by the disease, but also for Western people this countries business or pleasure for business or leisure trip. ‘.. Treatment – dates to confirm absence by side effects and benefits of easier treatment Schedule.
‘In If and and efficient, malarial can kill at just a couple days from flu symptoms,’malaria, which Umberto D’Allessando, Princeville Leopold Institute of Tropical Medicine, Antwerp, Belgium, coordinator one of the most trials.